GlassScriptPhysician profile
Michael Chien-Hui Yang
NPI 1043206022
$2,038.82
in general payments reported to CMS, 2019-2025
22 companies · $103 in 2025
The $103 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $379 · 2020: $182 · 2021: $369 · 2022: $316 · 2023: $380 · 2024: $310 · 2025: $103.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $793.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $792.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aerie Pharmaceuticals, INC. | $305.30 | 2019-2021 | |
| Abbvie INC. | $193.41 | 2022-2025 | Vuity, Alphagan P, Lumigan |
| Horizon Therapeutics Plc | $178.61 | 2022-2023 | Tepezza |
| Novartis Pharmaceuticals Corporation | $174.44 | 2019-2023 | |
| Sun Pharmaceutical Industries INC. | $163.49 | 2019-2024 | |
| Johnson & Johnson Surgical Vision, INC. | $130.47 | 2022-2023 | Tecnis Simplicity |
| Biotissue Holdings INC. | $121.40 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $113.05 | 2021 | |
| Dompe US, INC. | $93.03 | 2024 | Oxervate |
| Nevro Corp. | $91.42 | 2019 | |
| Bausch & Lomb Americas INC. | $69.58 | 2023-2024 | Xipere, Envista Mx60 Iol, Miebo |
| Johnson & Johnson Vision Care, INC. | $68.18 | 2020 | |
| Coopervision INC. | $64.26 | 2023-2024 | Myday Contact Lens, Paragon Crt |
| Allergan, INC. | $59.29 | 2019-2021 | |
| Oyster Point Pharma, INC. | $40.52 | 2022-2023 | Tyrvaya |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $34.05 | 2023 | Hydrus Microstent |
| Mallinckrodt Hospital Products INC. | $33.27 | 2021 | |
| Amgen INC. | $29.19 | 2024 | Tepezza |
| Shire North American Group INC | $24.65 | 2019 | |
| Tarsus Pharmaceuticals, INC. | $19.18 | 2024 | Xdemvy |
| Mayne Pharma Commercial LLC | $18.99 | 2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $13.04 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Yang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.